Angelini taps Sovargen for epilepsy drug in $550m deal Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.

#AngeliniPharma has licensed a preclinical-stage #mTORinhibitor from South Korean biotech #Sovargen with potential for genetic forms of #epilepsy and other brain disorders.